TriSalus Life Sciences, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-9.2M | $1.5M | $-9.8M | $-10.8M | $-8.3M | $-10.4M | $-10.1M | $-2.4M |
| Depreciation & Amortization | $136.0K | $135.0K | $126.0K | $163.0K | $165.0K | $172.0K | $193.0K | $182.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $2.6M | $2.5M | $2.2M | $3.4M | $1.9M | $1.6M | $1.7M | $1.4M |
| Net Cash from Operating Activities | $-10.1M | $-6.5M | $-2.5M | $-3.7M | $-7.3M | $-4.5M | $-5.7M | $-10.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $82.0K | $141.0K | $41.0K | $216.0K | $-93.0K | $754.0K | $50.0K | $169.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-82.0K | $-141.0K | $-41.0K | $-176.0K | $93.0K | $-714.0K | $-50.0K | $-169.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-54.0K | $42.4M | $277.0K | $82.0K | $20.7M | $9.7M | $3.0M | $5.8M |
| Net Change in Cash | $-10.3M | $35.8M | $-2.2M | $-3.8M | $13.5M | $4.5M | $-2.8M | $-5.2M |
| Free Cash Flow | $-10.2M | $-6.6M | $-2.5M | $-3.9M | $-7.2M | $-5.3M | $-5.8M | $-11.0M |